Fiche publication
Date publication
juillet 2025
Journal
European journal of heart failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Kalogeropoulos AP, Hameed I, Anker SD, Bayes-Genis A, Böhm M, Budden J, Cleland JGF, Coats AJS, Ezekowitz JA, Filippatos G, Goudev A, Khan MS, Lindenfeld J, Lund LH, Merkely B, Mentz RJ, Metra M, Moutchia J, Perrin A, Ponikowski P, Priest EL, Rossignol P, Senni M, Shaver C, Waechter S, Weir MR, Pitt B, Butler J
Lien Pubmed
Résumé
In the DIAMOND (Patiromer for the Management of Hyperkalaemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure) trial, the potassium binder patiromer enabled optimization of renin-angiotensin-aldosterone system inhibitors (RAASi) for patients with heart failure and a reduced ejection fraction (HFrEF) and current or recent hyperkalaemia. In this post-hoc analysis, we evaluated the effect of patiromer-enabled RAASi optimization on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, an established surrogate endpoint for clinical outcomes in HFrEF.
Mots clés
Guideline‐directed medical therapy, Heart failure with reduced ejection fraction, Hyperkalaemia, NT‐proBNP, Patiromer, Therapy optimization
Référence
Eur J Heart Fail. 2025 07 3;:
